Shareholders of Eckert & Ziegler SE (ISIN DE0005659700) voted in favor of a significantly higher dividend at the company's Annual General Meeting held today in Berlin. The meeting approved the Executive Board and Supervisory Board's proposal to distribute EUR 0.22 per share for the 2025 fiscal year, up from EUR 0.17 in the previous year. This increase underscores the company's robust financial health and its dedication to rewarding investors.
The Annual General Meeting, conducted as an in-person event near the company's headquarters in Berlin, saw representation of 55.37% of the share capital. All agenda items were endorsed by a large majority, including the ratification of the actions of the Executive Board and Supervisory Board for fiscal year 2025.
Eckert & Ziegler SE is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. With over 1,000 employees, the company provides a comprehensive range of services and products for the radiopharmaceutical industry, spanning from early development to contract manufacturing and distribution. The company's shares are listed in the TecDAX index of Deutsche Börse.
The dividend increase signals confidence in the company's ongoing growth and its ability to generate sustainable value. For investors, this move offers a tangible return on investment, reinforcing the stock's appeal within the healthcare sector. The decision also highlights the company's strategic focus on advancing life-saving medical technologies while maintaining strong corporate governance.
Detailed voting results and the CEO's presentation are available on the company's website: https://www.ezag.com/investors/annual-general-meeting/.
